Nihon Pharmaceutical Muscle Proteoglycan Patent, Apr 23
Summary
NIHON PHARMACEUTICAL CO., LTD. has filed patent application US20260108563A1 titled 'COMPOSITION FOR IMPROVING OR MAINTAINING MUSCLE QUANTITY OR MUSCLE STRENGTH', published April 23, 2026. The invention covers a novel method for producing proteoglycan by immersing a biological sample in an aqueous surfactant solution, and its use in improving muscle quantity or strength and preventing obesity or reducing body fat percentage. The application was originally filed on August 3, 2023 under application number 19100791, with Tatsuya Wada listed as inventor.
“The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO has published patent application US20260108563A1 for NIHON PHARMACEUTICAL CO., LTD., covering a proteoglycan composition for improving or maintaining muscle quantity or muscle strength and for preventing obesity or lowering body fat percentage. The production method involves immersing a biological sample comprising the proteoglycan in an aqueous surfactant solution and collecting the solution after immersion.
Affected parties include the pharmaceutical and nutraceutical industries focused on muscle health, obesity prevention, or body composition formulations. While the publication itself does not create immediate compliance obligations, competitors developing similar proteoglycan-based muscle or body-fat reduction products should conduct freedom-to-operate analyses to assess potential patent infringement risks once the application proceeds to grant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR IMPROVING OR MAINTAINING MUSCLE QUANTITY OR MUSCLE STRENGTH
Application US20260108563A1 Kind: A1 Apr 23, 2026
Assignee
NIHON PHARMACEUTICAL CO., LTD.
Inventors
Tatsuya WADA
Abstract
The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity. The proteoglycan used in the present invention is obtained by a method for producing the proteoglycan, comprising the steps of immersing a biological sample comprising the proteoglycan in an aqueous solution of a surfactant and collecting the solution after the immersion.
CPC Classifications
A61K 35/60 A61K 9/2009 A61K 9/2013 A61K 9/2054 A61P 21/00
Filing Date
2023-08-03
Application No.
19100791
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.